Zoetis Reports Mixed Q1 2026 Results Amid Pet Care Slowdown
Event summary
- Zoetis reported Q1 2026 revenue of $2.3B, up 3% YoY but flat organically.
- U.S. segment revenue declined 8% due to softer pet care demand and competitive pressure.
- International segment revenue grew 17% (10% organically), driven by livestock and diagnostics.
- Adjusted net income rose 2% to $646M, with adjusted EPS up 9% to $1.53.
- Zoetis announced plans to acquire Neogen's animal genomics business for livestock innovation.
The big picture
Zoetis' Q1 2026 results highlight the divergence between its U.S. and international segments, reflecting broader trends in pet care spending and livestock market dynamics. The company's strategic focus on innovation and acquisitions, particularly in livestock genomics, positions it to navigate competitive pressures while capitalizing on global demand for animal health solutions. With a diversified portfolio and strong pipeline, Zoetis aims to sustain long-term growth despite near-term challenges in premium pet care products.
What we're watching
- Market Segmentation
- How Zoetis will address the U.S. pet care slowdown while leveraging international growth.
- Execution Risk
- Whether the Neogen acquisition will successfully integrate and drive livestock innovation.
- Pipeline Performance
- The pace at which Zoetis' 12 potential blockbuster products advance through approvals.
Related topics